Navigation Links
New research could provide key to overcoming resistance to HER2 targeted cancer treatments
Date:6/10/2014

Dublin, Ireland, June 11th, 2014 Scientists from the School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin have made a significant discovery of a new biomarker which may help overcome resistance to newer and more targeted anti-cancer drugs, such as Herceptin, for HER2 positive cancers. These findings may also help the early identification of patients who will benefit more from these treatments.

The researchers, led by Professor Lorraine O'Driscoll, Associate Professor of Pharmacology, Trinity, studied breast cancer cells and their extracellular vesicles (exosomes), which are 'packages' of information released out of cells. They discovered a molecule called Neuromedin U (NmU) which is strongly associated with resistance to the new anti-cancer drugs for HER2 positive cancers. This suggests NmU could be used as a biological marker to indicate the likelihood of responsiveness in a particular patient and may also be very important in the management of resistance to these drugs. The findings have just been published in leading international, peer reviewed journal: Cancer Research, the most frequently cited cancer journal in the world.

About one quarter of breast cancer patients are known as being HER2 positive, where the protein HER2 is found at greater amounts on cancer cells compared to normal cells and which is associated with a poorer prognosis for the patient. A relatively new range of targeted anti-cancer drugs became available in recent years to treat patients with HER2 positive breast cancer and some other cancers such as HER2 positive gastric cancer. The best known one is Herceptin (trastuzumab), but there are other newer drugs in this family, including lapatinib, neratinib, afatinib, pertuzumab, T-DM1.

Speaking about the challenges some patients face with these newer anti-cancer drugs, Professor O'Driscoll said: "Many patients with HER2 positive tumours gain huge benefit from these drugs. Unfortunately, however, some who seem suitable candidates based on a HER2 test, don't gain the maximum intended benefit from these treatments. They may have a natural level of resistance to the treatment which is not detectable with currently available tests, while some other patients respond at first but may then become unresponsive or develop resistance to the treatments."

Professor O'Driscoll continued: "Clinicians urgently need ways of predicting which patients with 'HER2 tumours' are likely to gain real benefit, both to ensure patients are given the optimal treatments and to ensure these very costly drugs are used where they will have the most benefit. Our discovery may offer a new way to predict or identify both innate and acquired resistance, overcome it and potentially block or prevent resistance. This would allow patients to get the full benefit from these particular anti-cancer treatments and help other patients to be more quickly identified and receive the treatment options which are more appropriate for them."

The scientists also found that the levels of NmU outside the cells reflects that within the cells indicating it may be used as an 'extracellular' blood-based marker. This could allow clinicians to access and sample the levels of NmU through a minimally-invasive blood test compared to testing biomarkers within tissues.

They also found that by tweaking NmU's amounts in the cells, they could restore sensitivity to this family of anti-cancer drugs and offer an approach which may help prevent or overcome the serious resistance problem.

The research team conducted other studies which found that blocking NmU also significantly slowed the tumour's growth in the body and they plan to conduct further studies in this area.

The intellectual property has been protected to facilitate the translation of these discoveries to the benefit of patients with two patents pending in Europe and the US. This will be aided by the team's collaboration with the All Ireland Oncology Research Group (ICORG).


'/>"/>

Contact: Yolanda Kennedy
yokenned@tcd.ie
353-189-63551
Trinity College Dublin
Source:Eurekalert

Related biology news :

1. Researchers develop free online database for soybean studies
2. NYU and UCSF researchers develop a framework for monitoring oral cancer
3. Penn research develops onion vesicles for drug delivery
4. LSTM researchers identify the complex mechanisms controlling changes in snake venom
5. CU researchers explain mechanism that helps viruses spread
6. NHAES research: New England lakes recovering rapidly from acid rain
7. UNC researchers pinpoint new role for enzyme in DNA repair, kidney cancer
8. EcoHealth 2014 connects researchers addressing impacts of global change on health and ecosystems
9. Iowa State, Ames Lab researchers find the mechanism that forms cell-to-cell catch bonds
10. State of wildland fire emissions, carbon, and climate research
11. Race could be a factor in head and neck cancer survival rates, MU researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology: